Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphism

References

• Abbott Laboratories. (2000). Reductil [package insert]. North Chicago, IL: Abbott Park.
   Google Scholar
• Bae JW, Jang CG, Lee SY. (2011). Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites. J Clin Pharmacol 51:1704–1711.
   PubMed Web of Science ®Google Scholar
• Bae SK, Cao S, Seo KA, Kim H, Kim MJ, Shon JH, Liu KH, Zhou HH, Shin JG. (2008). Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes. Drug Metab Dispos 36:1679–1688.
   PubMed Web of Science ®Google Scholar
• Chang CI, Kim HA, Dua P, Kim S, Li CJ, Lee DK. (2011). Structural diversity repertoire of gene silencing small interfering RNAs. Nucleic Acid Ther 21:125–131.
   PubMedGoogle Scholar
• Cho JY, Lim HS, Chung JY, Yu KS, Kim JR, Shin SG, Jang IJ. (2004). Haplotype structure and allele frequencies of CYP2B6 in a Korean population. Drug Metab Dispos 32:1341–1344.
   PubMed Web of Science ®Google Scholar
• Chung JY, Jang SB, Lee YJ, Park MS, Park K. (2011). Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. J Clin Pharmacol 51:53–59.
   PubMed Web of Science ®Google Scholar
• Clarithromycin. (1996).Clarithromycin [package insert]. North Chicago, IL: Abbott Lab.
   Google Scholar
• Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K, Flockhart DA, Zanger UM. (2007). Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8:547–558.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol AL, Mertzanis P, Duan SX, Wright CE, Shader RI. (1998). Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences. Clin Pharmacol Ther 64:278–285.
   PubMed Web of Science ®Google Scholar
• Gundlah C, Martin KF, Heal DJ, Auerbach SB. (1997). In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: Sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther 283:581–591.
   PubMed Web of Science ®Google Scholar
• Hakala KS, Link M, Szotakova B, Skalova L, Kostiainen R, Ketola RA. (2009). Characterization of metabolites of sibutramine in primary cultures of rat hepatocytes by liquid chromatography-ion trap mass spectrometry. Anal Bioanal Chem 393:1327–1336.
   PubMed Web of Science ®Google Scholar
• Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. (1998). Thermogenic effects of sibutramine in humans. Am J Clin Nutr 68:1180–1186.
   PubMed Web of Science ®Google Scholar
• Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, Court MH. (2004). Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225–238.
   PubMedGoogle Scholar
• Hind ID, Mangham JE, Ghani SP, Haddock RE, Garratt CJ, Jones RW. (1999). Sibutramine pharmacokinetics in young and elderly healthy subjects. Eur J Clin Pharmacol 54:847–849.
   PubMed Web of Science ®Google Scholar
• James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL; SCOUT Investigators. (2010). Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363:905–917.
   PubMed Web of Science ®Google Scholar
• Kim KA, Song WK, Park JY. (2009). Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. Clin Pharmacol Ther 86:511–518.
   PubMed Web of Science ®Google Scholar
• Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, Schwab M, Zanger UM. (2005). Genetic variability of CYP2B6 in populations of African and Asian origin: Allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 15:861–873.
   PubMed Web of Science ®Google Scholar
• Lee SS, Lee SJ, Gwak J, Jung HJ, Thi-Le H, Song IS, Kim EY, Shin JG. (2007). Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther Drug Monit 29:455–459.
   PubMed Web of Science ®Google Scholar
• Meridia. (2004).Sibutramine hydrochlorde monohydrate [package insert]. North Chicago, IL: Abbott Laboratories.
   Google Scholar
• Niemi M, Neuvonen PJ, Kivistö KT. (2001). The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 70:58–65.
   PubMed Web of Science ®Google Scholar
• Nishiya Y, Hagihara K, Kurihara A, Okudaira N, Farid NA, Okazaki O, Ikeda T. (2009). Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. Xenobiotica 39:836–843.
   PubMed Web of Science ®Google Scholar
• Nisoli E, Carruba MO. (2000). An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 1:127–139.
   PubMedGoogle Scholar
• Park SY, Kang YS, Jeong MS, Yoon HK, Han KO. (2008). Frequencies of CYP3A5 genotypes and haplotypes in a Korean population. J Clin Pharm Ther 33:61–65.
   PubMedGoogle Scholar
• Park H, Kim CW, Kim SS, Park CW. (2009). The therapeutic effect and the changed serum zinc level after zinc supplementation in alopecia areata patients who had a low serum zinc level. Ann Dermatol 21:142–146.
   PubMed Web of Science ®Google Scholar
• Perrio MJ, Wilton LV, Shakir SA. (2007). The safety profiles of orlistat and sibutramine: Results of prescription-event monitoring studies in England. Obesity (Silver Spring) 15:2712–2722.
   PubMed Web of Science ®Google Scholar
• Richter T, Mürdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, Zanger UM. (2004). Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308:189–197.
   PubMed Web of Science ®Google Scholar
• Rodvold KA. (1999). Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 37:385–398.
   PubMed Web of Science ®Google Scholar
• Rohrbacher M, Kirchhof A, Geisslinger G, Lötsch J. (2006). Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance. Pharmacogenomics 7:995–1002.
   PubMed Web of Science ®Google Scholar
• Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP. (2004). Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5:895–931.
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, Oka S. (2004). Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319:1322–1326.
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. (2005). Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 77:553–559.
   PubMed Web of Science ®Google Scholar
• Westphal JF. (2000). Macrolide – induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 50:285–295.
   PubMed Web of Science ®Google Scholar
• Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, Shin JG, Shin SG. (2004). Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 76:104–112.
   PubMed Web of Science ®Google Scholar